The research team, led by Henan Wang and Xindi Liu with corresponding authors Liang Wang and Jia Cong, followed 96 consecutive patients treated between November 2022 and March 2025. All had relapsed or refractory B-cell malignancies, the population in which CAR-T products have shown their greatest success. The median age was 56.5 years, with an interquartile range of 46 to 66.5, reflecting the typical demographic of lymphoma patients referred for cellular therapy. Rather than relying on the older Common Terminology Criteria for Adverse Events alone, the investigators graded blood toxicity using the recently formalized immune effector cell-associated hematotoxicity framework, known as ICAHT, which distinguishes neutropenia, or N-ICAHT, from thrombocytopenia, or T-ICAHT, and tracks each on its own timeline.

That distinction matters clinically. Neutropenia strips patients of their main defense against bacterial and fungal infections, while thrombocytopenia raises the risk of spontaneous bleeding, including intracranial hemorrhage in the most severe cases. The two complications have different kinetics, different risk factors, and different management strategies, yet many earlier studies lumped them together under a single hematologic toxicity label. By separating them, the Beijing team could ask whether the predictors of a crashing neutrophil count differ from the predictors of a crashing platelet count, and the answer turned out to be yes, at least in degree.

The efficacy backdrop of the cohort was consistent with published experience. The overall response rate reached 78.3 percent at one month after infusion and settled to 65.5 percent at three months. Classical acute toxicities were common but rarely severe: cytokine release syndrome occurred in 74.0 percent of patients, yet only 2.1 percent experienced grade 3 or higher episodes, and immune effector cell-associated neurotoxicity syndrome appeared in 10.4 percent of patients, of which 5.2 percent were grade 3 or higher. These figures confirm that in experienced centers the inflammatory toxicities that dominated early CAR-T literature are now largely manageable, leaving hematologic recovery as the dominant safety concern.

The neutrophil data tell a stark story. Grade 3 to 4 neutropenia peaked at day 4 after infusion, when 71.9 percent of patients had severely depleted counts, and although most recovered, 34.7 percent still had severe neutropenia at day 28. Persistent suppression a month after infusion is the point at which infectious risk compounds, since patients remain on prophylactic antivirals and often prophylactic antibiotics, and any breakthrough infection can escalate rapidly. To predict who would fare worst, the team stratified patients using the CAR-HEMATOTOX score, a pre-infusion composite that incorporates baseline blood counts, inflammatory markers such as ferritin and C-reactive protein, and disease burden. The score was calculable in 86 patients, and 31 of them, or 36.0 percent, fell into the high-risk category of 2 or above.

The stratification worked. Severe early N-ICAHT, defined as grade 3 to 4 neutropenia in the early window after infusion, occurred in 16.1 percent of high-risk patients compared with 3.6 percent of low-risk patients, a statistically significant difference with a p value of 0.013. In multivariable logistic regression, where candidate predictors were first filtered through LASSO regression to avoid overfitting, a CAR-HEMATOTOX score of 2 or higher was the only significant predictor of severe early neutropenia, with an adjusted odds ratio of 4.04 and a 95 percent confidence interval of 1.01 to 22.17. For late neutropenia, a different factor emerged: patients who had received bridging therapy, meaning anti-cancer treatment given between lymphodepletion planning and CAR-T infusion, had an adjusted odds ratio of 4.25, with a confidence interval of 1.64 to 10.98, for developing late-phase neutropenia.

Thrombocytopenia told an even sharper story. High-risk patients by CAR-HEMATOTOX developed severe early T-ICAHT at a rate of 74.2 percent versus 25.5 percent in low-risk patients, and late T-ICAHT at 80.6 percent versus 47.3 percent, both differences highly significant with p values below 0.001. The CAR-HEMATOTOX score was the strongest adjusted predictor of both early and late thrombocytopenia, with adjusted odds ratios of 8.22 and 4.20 respectively. The authors suggest this stronger association for platelets may reflect the score’s inclusion of baseline platelet count and inflammatory burden, both of which directly bear on platelet production and consumption. Perhaps the most provocative observation was that 9 of the 10 patients who developed neurotoxicity, 90 percent, also developed thrombocytopenia. The team frames this as hypothesis-generating, noting it may point to shared endothelial injury pathways linking brain vascular leakage and platelet decline, while cautioning that residual confounding cannot be excluded in an observational design.

The study also addressed a long-running practical debate: whether the supportive care used to rescue blood counts might itself fan the inflammatory toxicities of CAR-T. Growth factor support with granulocyte colony-stimulating factor, G-CSF, was given to 78.1 percent of patients, and thrombopoietin receptor agonists, TPO-RA, to 48.9 percent. Neither intervention was associated with an increased rate of grade 3 or higher cytokine release syndrome or neurotoxicity. This is reassuring for clinicians who worry that stimulating recovering myeloid cells could amplify the cytokine storm, and it supports the increasingly common practice of early, aggressive count support in the weeks after infusion. The authors are careful to note that within the limits of the observational design, this finding cannot establish causality in either direction, but it removes a major practical objection to using these drugs.

What the study cannot do, by its own design, is settle questions of causation or generalize beyond a single center. As a retrospective cohort at one Chinese hospital, it captures real-world practice, including the bridging therapies and supportive care patterns actually used, but it lacks the randomization needed to prove that the CAR-HEMATOTOX score modifies risk rather than merely marking it. The confidence interval around the early neutropenia odds ratio, stretching from barely above 1 to more than 22, reflects the modest sample size of 96 patients. Still, the consistency of the signal across both neutropenia and thrombocytopenia, and its alignment with prior validation work on the score in European and American cohorts, strengthens the case that pre-infusion risk stratification should become routine.

The practical implications are immediate. Patients flagged as high risk before infusion could be considered for closer platelet monitoring, earlier thrombopoietin receptor agonist initiation, lower thresholds for transfusion, and heightened vigilance for neurologic symptoms given the observed overlap with ICANS. The finding that bridging therapy predicts late neutropenia adds weight to the argument for minimizing or carefully selecting pre-infusion treatment in patients who can safely proceed directly to CAR-T. As CAR-T therapy expands beyond academic centers into community oncology, tools like the CAR-HEMATOTOX score offer a way to bring sophisticated risk assessment to settings without specialized cellular therapy infrastructure. The Beijing cohort suggests that the era of treating CAR-T hematotoxicity as an unpredictable hazard is ending, replaced by a framework in which the patients most likely to crash are identifiable before the first engineered cell is infused.

Subject of Research: Hematologic toxicity, including neutropenia and thrombocytopenia, following CAR-T cell therapy for B-cell malignancies

Article Title: Analysis of hematologic toxicity profiles following CAR-T cell therapy: a retrospective cohort study

Article References: Wang, H., Liu, X., Li, F., Liang, Y., Zeng, L., Zhu, J., Wang, L., & Cong, J. (2026). Analysis of hematologic toxicity profiles following CAR-T cell therapy: a retrospective cohort study. BMC Cancer. https://doi.org/10.1186/s12885-026-16932-0

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16932-0

Keywords: CAR-T cell therapy, ICAHT, neutropenia, thrombocytopenia, CAR-HEMATOTOX, hematologic toxicity, B-cell malignancy, cytokine release syndrome, ICANS, G-CSF, thrombopoietin receptor agonist, retrospective cohort study

The research team, led by Eilidh M. Duncan of Myeloma Patients Europe in Brussels, brought together an unusually diverse group of 38 participants to tackle the problem. Rather than consulting only clinicians or researchers, the investigators recruited patients with direct experience of CAR-T or bispecific antibody treatment, informal family carers, patient advocates from myeloma, lymphoma, and leukaemia communities, academic researchers, trialists, pharmaceutical industry representatives, and officials from regulatory and health technology assessment bodies, including the FDA and EMA. Data came from 14 one-to-one interviews with 16 participants and two online focus groups involving 15 and 19 participants respectively. Transcripts were analysed using a deductive-inductive thematic approach with double coding by independent researchers, a methodological rigor that strengthens the credibility of the resulting themes.

The technical context makes the challenge clear. CAR-T therapy involves engineering a patient’s own T cells to recognise cancer cells, while bispecific antibodies, or BsAbs, are laboratory-made molecules that physically link T cells to malignant cells. Both can trigger cytokine release syndrome, an immune overreaction causing fever, nausea, headache, low blood pressure, and potentially multi-organ failure. They can also cause immune effector cell-associated neurotoxicity syndrome, or ICANS, a neuropsychiatric condition ranging from mild tremor and confusion to haemorrhage, coma, and death. According to the study, CRS occurs in roughly 87 percent of CAR-T patients and 67 percent of those receiving BsAbs, while neurotoxicity affects 40 to 64 percent of CAR-T recipients, with 27 percent requiring intensive care admission. These acute toxicities typically emerge within one to four weeks after treatment, yet longer-term experiences are rarely assessed or reported.

One of the most striking findings concerns the logistical maze surrounding CAR-T treatment. Because the therapy is only available at specialised centres, patients frequently travel more than 100 kilometres for infusion and hospitalisation, then return to local providers for follow-up. This fragmentation across multiple treatment sites complicates PROM data capture and contributes to missing data. Participants also highlighted a sobering measurement paradox: patients experiencing the worst toxicities, such as cognitive impairment from ICANS or severe CRS, are often too unwell to complete questionnaires at all. As one researcher explained, the data dip between pre-lymphodepletion and week two captures only the sick patients who are still fit enough to fill out forms, not the sickest ones, making the reasons for missing data critically important to understand.

Bispecific antibodies present their own distinct measurement headache. Unlike CAR-T, which is a fixed-duration treatment, BsAbs involve continuous administration with a wide variety of side effects occurring over different time periods. Participants described agents such as talquetamab, a GPRC5D-targeting bispecific, which produces gastrointestinal effects, skin toxicity, complete taste loss, falling nails, itchy rashes, and weight loss. Some symptoms resolve over several months while others, like taste changes and weight loss, persist indefinitely. These treatment-specific domains fall outside the scope of generic instruments such as the EORTC QLQ-C30, which was designed for broad applicability rather than therapy-specific sensitivity. A recent review found 15 distinct PROMs used within just 16 CAR-T studies, highlighting the heterogeneity that undermines evidence synthesis across trials.

The timing of assessments emerged as a central controversy. Participants broadly agreed that baseline measurements for CAR-T and BsAbs trials should occur earlier than for older anticancer therapies, yet uncertainty persists about what baseline actually means. Because the CAR-T process spans several weeks, including leukapheresis, bridging therapies, and hospitalisation, a patient’s disease status and quality of life can shift dramatically between initial stages and infusion. Several researchers argued that future analyses should include two baselines, one right before lymphodepletion and one at the time of apheresis. Health technology assessment representatives insisted that baseline should mean study baseline, tied to treatment decision or randomisation, not any later time point.

Follow-up timing proved equally contentious. Participants suggested assessments as early as one week after infusion could serve as a crucial anchor point to capture the frequency, intensity, severity, and resolution of side effects. Industry representatives acknowledged the feasibility challenges, noting that patients are often hospitalised and facing severe complications like CRS shortly after infusion. For BsAbs with step-up dosing, where patients receive three doses during week one, some argued quality of life and toxicity should be explored after each individual dose. A regulatory representative called for weekly assessments during the first two months after CAR-T administration, using an item library to select really important symptoms such as headache and fatigue, alongside physical functioning measured on a high-frequency basis.

Perhaps the most emotionally resonant finding concerns what current PROMs systematically miss. Patients described the intense mental strain of waiting for CAR-T, including fear that their health would deteriorate during the manufacturing interval and render them ineligible. One patient recounted that doctors and nurses focused on physical side effects while never asking about the mental part, which was the most difficult aspect, and that her doctor essentially told her the mental part was hers to handle alone. Participants also flagged emerging concepts like time toxicity, meaning the time patients spend managing treatment and its effects, along with the burden on family carers, financial strain, and the psychological weight of living with an immunocompromised state. None of the three commonly used PROMs in trials, the EORTC QLQ-C30, MDASI-CAR, and PRO-CTCAE, capture waiting anxiety, logistical burden, caregiver burden, or treatment-free survival.

The study’s recommendations form a concrete blueprint for reform. The authors propose a dual-baseline strategy appropriate for rapid clinical changes preceding CAR-T infusion, mandated early high-frequency assessments, meaning weekly for the first four weeks, systematic inclusion of patient-important domains currently under-captured such as emotional well-being and time toxicity, continued PRO data collection beyond clinical progression, and transparent, comprehensive reporting of PRO findings. They also endorse interim strategies like combining instruments, adding PRO-CTCAE items to primary measures, and incorporating qualitative interviews or free-text responses. Longer-term, they support developing new treatment-specific PROMs, potentially with a modular core-plus-supplement design, alongside computerised adaptive testing to tailor questionnaires to individuals and reduce respondent burden.

The stakes extend far beyond academic measurement. CAR-T and BsAbs are high-cost therapies whose cost-effectiveness for health systems remains controversial, and PROM data directly informs reimbursement decisions. Under-reporting PRO data, the authors argue, is not just a concern for research validity but an unethical waste of patients’ time and energy, breaking the implicit agreement that patients’ contributions will meaningfully inform knowledge generation. Patients were willing to complete PROMs when they understood how their data would be used and felt confident it would not be wasted. As these immunotherapies continue to expand across haematological malignancies, the gap between what patients endure and what trials record can no longer be ignored. Clearer guidance from regulators and payers on instrument selection, assessment schedules, and reporting would substantially improve the quality and patient-centredness of evidence in this rapidly evolving field.

Subject of Research: Optimisation of patient-reported outcome measures for haematological cancer patients receiving CAR-T and bispecific antibody immunotherapies

Article Title: Optimisation of patient-reported outcome measurement for haematological cancer patients receiving novel immunotherapies: perspectives of multi-stakeholders

Article References: Duncan, E. M., Salviano, J., Kyriakou, C., Nier, S., Oerlemans, S., Salek, S., Morgan, K., & Joyner, K. (2026). Optimisation of patient-reported outcome measurement for haematological cancer patients receiving novel immunotherapies: perspectives of multi-stakeholders. Frontiers in Hematology, 5, Article 1800304. https://doi.org/10.3389/frhem.2026.1800304

Image Credits: AI Generated

DOI: 10.3389/frhem.2026.1800304

Keywords: CAR-T therapy, bispecific antibodies, patient-reported outcomes, PROMs, haematological malignancies, cytokine release syndrome, ICANS, quality of life, clinical trials, time toxicity, regulatory guidance, survivorship

The therapy itself is a feat of cellular engineering. Clinicians harvest a patient’s own T lymphocytes, genetically reprogram them in the laboratory with a viral vector that encodes a chimeric antigen receptor recognizing CD19—a protein displayed on nearly all malignant B cells—expand the modified cells to billions, and reinfuse them after lymphodepleting chemotherapy. The engineered cells then hunt down and destroy CD19-bearing tumor cells wherever they find them, including, crucially, within the immune-privileged sanctuary of the central nervous system. That last point matters enormously, because the pivotal registration trials for the three commercially approved products—axicabtagene ciloleucel, tisagenlecleucel and lisocabtagene maraleucel—largely excluded patients with CNS involvement. The worry was twofold: that the cells might not cross the blood-brain barrier in sufficient numbers, and that activating potent immune cells near the brain could trigger catastrophic neurotoxicity.

Those concerns kept CNS lymphoma patients, the very people with the fewest alternatives, out of the trials that defined the field. Evidence for them accumulated instead in retrospective cohorts, registry studies and small prospective series, each too limited to settle the question. The new analysis, conducted in accordance with PRISMA guidelines and prospectively registered in PROSPERO, set out to synthesize that fragmented literature into usable estimates. The investigators systematically searched PubMed, Google Scholar, Semantic Scholar, ClinicalTrials.gov and the Cochrane Library from inception to 31 August 2025, screening 1,247 records down to 23 eligible studies—18 retrospective and 5 prospective—comprising 547 adults who had typically received at least two prior lines of therapy.

The pooled survival figures carry real weight for a population with otherwise vanishing options. Twelve-month overall survival reached 64.5 percent, with a 95 percent confidence interval spanning 49.0 to 76.0 percent, and 12-month progression-free survival was 51.0 percent, with a wider interval of 35.0 to 68.0 percent. Given that historical outcomes after CNS lymphoma relapse are often measured in a handful of months, a median expectation of roughly a year progression-free for half of all comers represents a genuine shift. The estimates are comparable to those reported in the landmark trials of CAR T-cell therapy for systemic large B-cell lymphoma, suggesting that the blood-brain barrier, once feared as an impenetrable obstacle, does not negate the therapy’s activity.

Response data, analyzed separately for the two disease subtypes, add nuance. Patients with primary CNS lymphoma, in which the malignancy originates in the brain, achieved a pooled complete response rate of 52 percent, with remarkably consistent results across studies—heterogeneity sat at just 32 percent. Secondary CNS lymphoma, which arises when systemic lymphoma spreads into the nervous system, fared somewhat less well, with a pooled complete response rate of 40 percent and moderate heterogeneity of 76 percent. The authors attribute the gap to disease biology: secondary involvement typically coincides with uncontrolled systemic disease and higher tumor burden, both of which erode the odds that even a powerful cellular therapy can reset. Sensitivity analysis showed that a single large EBMT registry study contributed substantially to that heterogeneity; excluding it dropped the figure to 40 percent.

Safety has always been the central anxiety for this indication, and the analysis addresses it directly. Cytokine release syndrome—the systemic inflammatory cascade unleashed when massive numbers of immune cells activate simultaneously—occurred in 76 percent of PCNSL patients and 77 percent of SCNSL patients, but with zero heterogeneity across studies, meaning the rate was startlingly uniform. Immune effector cell-associated neurotoxicity syndrome, the cerebral edema and encephalopathy spectrum that gave trial designers pause, occurred in 50 percent of PCNSL patients and 46 percent of SCNSL patients. Crucially, most events on both fronts were low to moderate in severity and reversed with standard supportive care: tocilizumab, the interleukin-6 receptor antibody that has become the workhorse for CRS, and corticosteroids for neurotoxicity. The rates are broadly consistent with those seen in systemic lymphoma populations, though the authors caution that the analysis lacked a non-CNS comparator arm for direct comparison.

Methodological rigor underpins the estimates. The team used a random-effects model of proportions with the Freeman-Tukey double arcsine transformation to stabilize variance, quantified heterogeneity with the I² statistic, and performed leave-one-out sensitivity analyses to test robustness. Survival probabilities were extracted from Kaplan-Meier curves where necessary, verified independently by two reviewers, and corresponding authors were contacted for missing data. Risk of bias was formally assessed with the ROBINS-I tool, yielding a sobering distribution: seven studies at low risk, seven at moderate risk and nine at serious risk, with retrospective design, confounding and selective participant selection the recurring culprits. Funnel plot inspection found no obvious asymmetry, but the small number of studies per outcome limits how much can be read into that.

The heterogeneity statistics themselves tell an honest story. Overall survival pooled at moderate heterogeneity of 67.6 percent, and progression-free survival at high heterogeneity of 80.2 percent, reflecting the mosaic of patient characteristics, tumor burdens, prior regimens and CAR T-cell constructs stitched together across the included studies. Some patients received axicabtagene ciloleucel, others tisagenlecleucel or lisocabtagene maraleucel, and several trials—particularly from Chinese centers—tested locally manufactured CD19 or CD19/CD22 bispecific constructs. Median follow-up ranged from 5.1 to 37.5 months, clustering around one year, which is precisely the horizon over which the pooled estimates are calculated and too short to say whether deep remissions will hold at three or five years. Disease-specific survival pooling was also impossible, because most studies reported combined outcomes without adequate subgroup data.

Those limitations do not diminish the clinical signal; they simply bound it. For relapsed or refractory CNS lymphoma, where the previous standard of care offered little more than palliation, a therapy that produces complete responses in roughly half of primary CNS lymphoma patients and keeps half of all patients progression-free at one year, with toxicities that are frequent but manageable, has earned a place in the treatment algorithm. The finding that CAR T cells can operate effectively behind the blood-brain barrier also validates years of mechanistic work suggesting the barrier, while restrictive to antibodies and small molecules, is navigable by activated lymphocytes—whether they arrived there naturally or were engineered to be lethal.

What the field needs next is unambiguous. The authors call for large prospective multicentre trials with standardized outcome reporting and longer follow-up to define durability, late relapse patterns and long-term safety, and to determine which product, bridging strategy and consolidation approach works best for which subtype. Open questions abound: whether sequential CD19/CD22 targeting can forestall antigen-loss relapse, how lymphodepletion intensity shapes CNS penetration, and whether minimal residual disease monitoring can identify failing responders early enough for salvage. Until those trials mature, the pooled evidence positions CD19-directed CAR T-cell therapy as the most credible lifeline yet for a disease that, until recently, offered almost none.

Subject of Research: Efficacy and safety of CD19-directed CAR T-cell therapy for relapsed or refractory primary and secondary central nervous system lymphoma

Article Title: Efficacy and Safety of CAR T‐Cell Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review and Meta‐Analysis

Article References: Khan, A., Malik, A. A., Kareem, W., Idrees, M., Kamil, K. A., Irshad, K., Baig, Z. M., Yahya, A., Qureshi, W., Ahmad, M., & Bilanda, B. (2026). Efficacy and Safety of CAR T‐Cell Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review and Meta‐Analysis. eJHaem, 7(5), Article e70407. https://doi.org/10.1002/jha2.70407

Image Credits: AI Generated

DOI: 10.1002/jha2.70407

Keywords: CAR T-cell therapy, central nervous system lymphoma, PCNSL, SCNSL, CD19, meta-analysis, cytokine release syndrome, ICANS, immunotherapy, hematologic malignancy, overall survival, blood-brain barrier

The case centers on a patient who, after receiving CAR T cell therapy, developed signs of profound neurological injury. Brain magnetic resonance imaging revealed abnormalities characteristic of immune effector cell-associated neurotoxicity syndrome, universally abbreviated as ICANS: fluid-attenuated inversion recovery sequences showed periventricular white matter hyperintensities involving the atrium and temporal horn of the lateral ventricles, while diffusion-weighted imaging demonstrated areas of cytotoxic edema within the hippocampi on both sides. But what made the case exceptional was the spinal imaging. T2-weighted magnetic resonance images of the spine disclosed a longitudinally extensive spinal cord lesion, with abnormal signal intensity extending over more than three vertebral body segments. Critically, the lesion showed no enhancement after gadolinium administration on post-contrast T1-weighted images.

That combination of findings, a long spinal cord lesion that refuses to light up with contrast, is diagnostically treacherous. In clinical practice, a longitudinally extensive T2 hyperintense lesion in the spinal cord is nonspecific and can be produced by infectious, autoimmune, or vascular processes. Acute autoimmune inflammation of the spinal cord, or ischemia-related breakdown of the blood-spinal cord barrier, typically produces contrast enhancement, because the damaged barrier allows the gadolinium to leak into the cord tissue. A non-enhancing lesion therefore sits uneasily with the classic picture of acute inflammatory myelitis. The Paris team reasoned that, given the concurrent brain lesions suggestive of ICANS and the exclusion of infectious causes, the most likely diagnosis was spinal cord involvement as a component of ICANS itself, a manifestation so rare that only a handful of cases have been described in the literature, and those published reports describe similar non-enhancing imaging features.

The first and most urgent diagnostic step the authors emphasize is the systematic exclusion of infectious myelitis. This is not a bureaucratic precaution. Patients who have undergone CAR T cell therapy are profoundly immunocompromised, both from the lymphodepleting chemotherapy that precedes the infusion and from the therapy’s effects on normal B cells and other immune populations. In such patients, opportunistic infections of the central nervous system are a constant threat. The authors single out viral etiologies that must always be considered: cytomegalovirus, herpes simplex virus, varicella-zoster virus, enteroviruses, and human herpesvirus-6, each of which can produce devastating spinal cord disease in the immunosuppressed host. In their patient, cerebrospinal fluid cultures and multiplex polymerase chain reaction testing were negative, making an infectious etiology unlikely and clearing the way for the diagnosis of ICANS-associated myelopathy.

Understanding why this matters requires appreciating what ICANS is and how it usually behaves. Immune effector cell-associated neurotoxicity syndrome is the most feared non-hematological toxicity of CAR T cell therapy, typically emerging days after infusion as the engineered cells expand and release inflammatory cytokines. It usually announces itself with aphasia, confusion, tremor, and, in severe cases, seizures, cerebral edema, and coma. Aseptic meningitis is a common feature, and brain imaging may show transient abnormalities. The syndrome is graded from I to IV, with grade IV representing life-threatening neurotoxicity. Standard management escalates from corticosteroids to the interleukin-1 receptor antagonist anakinra for severe disease. But the spinal cord has been largely absent from this picture, which is precisely why the Paris case is so valuable to the field.

The timing of spinal cord involvement poses its own diagnostic puzzle, and the authors are candid about this uncertainty. In patients with severe ICANS, concomitant severe encephalopathy frequently precludes a complete neurological examination. A patient who is obtunded or comatose cannot report numbness, weakness, or a sensory level, and the examiner cannot reliably test for the signs that would localize a spinal cord lesion. As a result, it is often impossible to determine when spinal cord symptoms first occur, or whether they emerged before, alongside, or after the encephalopathy. In the reported patient, cerebral and spinal cord involvement probably developed simultaneously, a synchrony that itself supports the idea that both represent facets of a single systemic neurotoxic process rather than two independent complications.

Therapeutically, the patient received the recommended treatment for grade IV ICANS: high-dose corticosteroids combined with anakinra, the interleukin-1 receptor antagonist that has become the mainstay of salvage therapy for steroid-refractory neurotoxicity. Beyond this standard regimen, however, the evidence base evaporates. The authors state plainly that there is no clear evidence supporting a specific therapeutic strategy for ICANS-associated myelopathy. Interventions that neurologists might reach for in other forms of acute myelitis, such as intravenous immunoglobulins or plasmapheresis, have no established role here, because the underlying biology of the spinal cord lesion remains obscure. Larger case series, the authors argue, are needed to define the optimal treatment and the prognosis of this rare manifestation.

The imaging findings deserve close attention from clinicians who will face similar dilemmas. The pattern reported here, a long T2-hyperintense cord lesion without contrast enhancement, occurring in a patient with hippocampal cytotoxic edema and periventricular white matter changes, effectively constitutes a signature that others can look for. The hippocampal involvement is particularly suggestive, because bilateral cytotoxic edema in the hippocampi has been described in severe CAR T cell neurotoxicity and reflects the vulnerability of this region to the inflammatory and possibly vascular disturbances that ICANS produces. When such brain findings are accompanied by a non-enhancing longitudinal cord lesion in a recently infused patient, ICANS-associated myelopathy moves to the top of the differential diagnosis, provided infection has been rigorously excluded.

The broader significance of the case lies in the growing recognition that CAR T cell neurotoxicity is not confined to the brain. As the therapy expands from refractory lymphomas and multiple myeloma into earlier lines of treatment and into autoimmune diseases, the population of exposed patients is growing rapidly, and rare complications become clinically meaningful at scale. Reports such as this one, published as part of the journal’s imaging series with practical tips for intensivists, serve as sentinels. They alert critical care physicians, neurologists, and hematologists that when a CAR T cell recipient deteriorates neurologically, the evaluation must extend beyond the cranial vault. Spinal imaging, cerebrospinal fluid analysis with multiplex pathogen testing, and careful correlation of brain and cord findings should be part of the diagnostic armamentarium.

For now, the message from the Paris team is one of disciplined caution. Infectious myelitis must be systematically ruled out before attributing a cord lesion to ICANS, because the treatments differ fundamentally and the stakes are enormous. The non-enhancing character of the lesion, while atypical for classic autoimmune myelitis, appears consistent across the few published cases of ICANS-associated myelopathy and may reflect a distinct pathophysiology, perhaps one that does not disrupt the blood-spinal cord barrier in the way conventional inflammation does. Until larger series clarify the mechanism, the optimal treatment, and the long-term prognosis of this unusual complication, the case stands as both a warning and a guide: the engineered immune cells that save lives can, in rare instances, reach beyond the brain, and clinicians must be ready to recognize when they do.

Subject of Research: Acute myelopathy as a rare manifestation of CAR T cell therapy-associated neurotoxicity

Article Title: Acute myelopathy following chimeric antigen receptor (CAR) T cell therapy: an unusual diagnostic challenge

Article References: Bois, A., Provost, C., Decroocq, J., & Benghanem, S. (2026). Acute myelopathy following chimeric antigen receptor (CAR) T cell therapy: an unusual diagnostic challenge. Intensive Care Medicine. https://doi.org/10.1007/s00134-026-08617-w

Image Credits: AI Generated

DOI: 10.1007/s00134-026-08617-w

Keywords: CAR T cell therapy, ICANS, neurotoxicity, myelopathy, spinal cord, immune effector cell, MRI, encephalopathy, anakinra, corticosteroids, immunocompromised, intensive care

The biology of CRS begins the moment engineered T cells recognize their target. CAR T cells are autologous lymphocytes genetically modified to express synthetic receptors that bind tumor-associated antigens such as CD19 or BCMA. Upon antigen engagement, the cells unleash perforin and granzyme to kill malignant cells while simultaneously secreting a cocktail of pro-inflammatory signaling proteins, including interferon-gamma, tumor necrosis factor alpha, GM-CSF, and interleukin-2. These signals then recruit and activate innate immune players, chiefly monocytes and macrophages, which respond by pouring out interleukin-6 and interleukin-1 beta. This amplification loop between adaptive and innate immunity is what transforms a targeted attack into a systemic cytokine storm. Vascular endothelial cells become activated, blood vessels leak, and patients develop the classic clinical picture: fever, fatigue, hypotension, hypoxia, and in the worst cases multi-organ dysfunction. In severe instances, the syndrome can escalate into an immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome and contribute to disruption of the blood-brain barrier, setting the stage for neurological complications.

How sick a patient becomes is not a matter of chance. Tumor burden at baseline, the specific CAR construct used, and the magnitude of T-cell expansion all shape the intensity of the inflammatory response. The intracellular costimulatory domain built into the receptor plays a particularly important role: constructs carrying the CD28 domain drive rapid T-cell expansion and are associated with a higher incidence of acute, severe adverse events, whereas 4-1BB-based constructs expand more slowly and persistently, producing a more gradual and generally less toxic immune response. Higher CAR T-cell doses enhance antitumor efficacy but also raise the risk of massive simultaneous T-cell activation. Patient factors matter as well. Elevated pre-infusion inflammatory markers such as interleukin-6 and C-reactive protein, advanced age, cardiovascular or renal comorbidities, certain lymphoma subtypes including primary mediastinal B-cell lymphoma, and pediatric or young adult patients treated for acute lymphoblastic leukemia all signal elevated risk. Bridging therapy to shrink the tumor before infusion is one practical strategy to lower the odds of explosive cytokine release.

Accurate grading is the backbone of treatment decisions. The consensus system from the American Society for Transplantation and Cellular Therapy classifies CRS into four grades based on fever, hypotension, hypoxia, and organ toxicity, deliberately moving beyond fever alone to incorporate the need for vasopressors and supplemental oxygen. Grade 1 disease, essentially fever by itself, is usually managed conservatively with antipyretics and observation. Grade 2, marked by hypotension or mild hypoxia, requires hospital monitoring and often pharmacologic intervention. Grade 3 and 4 cases, involving refractory low blood pressure, multisystem injury, shock, or respiratory failure, demand escalation to corticosteroids, vasopressors, and intensive care, with mechanical ventilation reserved for the critically ill. Because the boundary between CRS and sepsis can be blurred, clinicians must constantly weigh early immunosuppression against the danger of masking an underlying infection, a balancing act that defines much of the day-to-day management of these patients.

At the center of the pharmacologic arsenal sits tocilizumab, a monoclonal antibody that blocks the interleukin-6 receptor and remains the only drug approved by the FDA specifically for CRS. By interrupting the interleukin-6 signaling axis, it rapidly reverses fever, hypotension, and capillary leak without impairing the antitumor activity of the CAR T cells, and in most patients one or two doses suffice to control grade 2 or higher disease. Its speed has made it the emergency drug of choice, stocked in treatment centers with STAT ordering protocols. But tocilizumab is not without caveats. Blocking the receptor can cause circulating interleukin-6 levels to rebound, and there is concern that unbound cytokine may then cross the blood-brain barrier, potentially triggering or worsening immune effector cell-associated neurotoxicity syndrome, known as ICANS. This interplay between the two syndromes complicates therapy, since ICANS typically emerges days after CRS onset and, unlike CRS, does not respond to tocilizumab because the antibody penetrates the central nervous system poorly.

For patients who fail interleukin-6 blockade or who develop neurological symptoms, corticosteroids such as dexamethasone and methylprednisolone serve as the crucial second line. Historical worries that steroids might blunt CAR T-cell proliferation have been tempered by more recent evidence showing that early administration at moderate doses and limited duration does not significantly compromise antitumor efficacy. Typical regimens involve intravenous dexamethasone at 10 milligrams every six hours or methylprednisolone at 1 to 2 milligrams per kilogram per day, tapered over three to five days according to clinical response. Beyond steroids, a growing set of targeted agents is expanding the toolkit. Anakinra, an interleukin-1 receptor antagonist, crosses the blood-brain barrier readily and is increasingly valued for tocilizumab-refractory CRS and concurrent neurotoxicity. Lenzilumab, targeting GM-CSF, and emapalumab, targeting interferon-gamma, are under clinical evaluation for severe or steroid-refractory disease. In a striking example of drug repurposing, the beta-blocker metoprolol has been shown in laboratory and clinical studies to directly inhibit interleukin-6 translation in human monocytes, reducing CRS severity without harming CAR T-cell function and opening a novel therapeutic target: the protein synthesis machinery of inflammatory cells.

Monitoring is where modern CRS care increasingly meets data science. Routine protocols call for daily ferritin, C-reactive protein, and cytokine panels during the first ten days after infusion, or longer in high-risk patients, because rising interleukin-6, ferritin, and CRP levels precede clinical symptoms and correlate with severity. Soluble interleukin-2 receptor and coagulation markers flag the hemophagocytic syndrome variant and coagulopathy. Artificial intelligence is now pushing surveillance further. A model called PrCRS, built on U-Net and Transformer architectures with transfer learning, can predict severe CRS one to three days before symptom onset. Other multimodal machine learning systems analyze vital signs, laboratory results, and early cytokine profiles to identify high-risk patients within hours of infusion, and an explainable algorithm proposed by Bogatu and colleagues incorporates domain literature to detect CRS from cytokine peak levels despite limited training data. Real-time dashboards linked to electronic health records are already being piloted at academic centers, alerting care teams and enabling preemptive tocilizumab or steroid administration based on algorithmic triggers.

None of these tools work in isolation, and the review emphasizes that the hallmark of contemporary CRS management is multidisciplinary coordination. Optimal outcomes emerge when hematologists, oncologists, intensivists, neurologists, infectious disease specialists, pharmacists, and specialized nurses operate under unified protocols with rapid triage pathways and seamless escalation from ward to intensive care. Many centers have established cellular therapy toxicity boards, early warning systems, and dedicated CAR T-cell response teams equipped with predesigned protocols, immediate drug access, and intensive care beds on standby. Standardized operating procedures embed CRS and ICANS flowcharts directly into electronic medical records, while simulation training for nurses and residents sharpens recognition of early warning signs. Age also shapes strategy: pediatric patients generally tolerate higher cytokine loads, so clinicians lean on supportive care and reserve steroids for refractory cases, whereas elderly patients, vulnerable to cardiovascular and renal decompensation, warrant a lower threshold for early intervention, cardiac monitoring, and bridging therapy to reduce disease burden before infusion.

Looking ahead, the field is moving from reactive treatment to engineered prevention. Ruxolitinib, a Janus kinase 1/2 inhibitor, dampens downstream signaling from multiple cytokines and may help when interleukin-6 blockade alone is insufficient. Siltuximab, which binds interleukin-6 directly rather than its receptor, offers an alternative where receptor blockade falls short. More radically, next-generation CAR constructs are being designed with safety built in: bispecific and split-signaling receptors that require dual-antigen recognition to activate, ON/OFF-switch systems controlled by administered small molecules, suicide genes such as inducible caspase 9, and so-called armored CARs that co-express anti-cytokine payloads like interleukin-1 receptor antagonists to neutralize inflammation at its source. Researchers are also probing the upstream triggers of CRS, implicating inflammasome activation, pyroptotic cell death, and tissue-resident macrophages, and pursuing multi-omics biomarker discovery to shift management from reactive to proactive. Together, these advances promise to widen the therapeutic window of CAR T-cell therapy, allowing its remarkable curative potential to reach broader and more fragile patient populations safely.

Subject of Research: Management of cytokine release syndrome following CAR T-cell therapy

Article Title: Management of Cytokine Release Syndrome (CRS) following CAR T-cell therapy: a comprehensive review

Article References: Zhang, Y., & Han, W. (2025). Management of Cytokine Release Syndrome (CRS) following CAR T-cell therapy: a comprehensive review. Clinical Cancer Bulletin, 4(1), Article 15. https://doi.org/10.1007/s44272-025-00044-0

Image Credits: AI Generated

DOI: 10.1007/s44272-025-00044-0

Keywords: CAR T-cell therapy, cytokine release syndrome, tocilizumab, ICANS, immunotherapy toxicity, interleukin-6, corticosteroids, anakinra, biomarkers, artificial intelligence prediction, risk stratification, hematological malignancies

Tarlatamab is a bispecific T-cell engager, a designed molecule that simultaneously binds DLL3, a protein abundant on small cell lung cancer cells, and CD3 on T cells, physically drawing immune effector cells into contact with tumor cells and triggering cancer cell killing. When administered at 10 mg every two weeks, the drug has previously demonstrated superior overall survival compared with chemotherapy in patients whose disease had progressed after first-line treatment, a milestone that reshaped expectations for this notoriously aggressive malignancy. The central question of DeLLphi-309 was whether less frequent administration, at higher individual doses, could deliver comparable outcomes while easing the burden of frequent clinic visits.

In the trial, adults whose small cell lung cancer had progressed or recurred after first-line platinum-based chemotherapy were randomized to one of three intravenous regimens: 10 mg every two weeks, 20 mg every three weeks, or 30 mg every four weeks, each following a 1 mg step dose designed to mitigate initial immune-related toxicity. The primary endpoint was confirmed objective response rate as assessed by blinded independent central review. No formal statistical hypotheses were prespecified, and the findings were presented descriptively, meaning the results should be interpreted as exploratory rather than definitive comparative evidence.

As of May 7, 2026, 252 patients had been randomized across the three arms. Blinded independent central review confirmed objective response rates of 40% in the every-two-week group, 31% in the every-three-week group, and 27% in the every-four-week group. Investigator-assessed response rates told a somewhat more compressed story, at 36%, 37%, and 31%, respectively, highlighting how assessment methodology can influence the apparent magnitude of differences between schedules. Median progression-free survival by blinded independent central review was 4.2 months with the established every-two-week regimen, 4.1 months with the every-three-week schedule, and 2.7 months with the every-four-week schedule.

Overall survival data, while immature, added further nuance to the picture. Six-month overall survival rates were 72% with the every-two-week regimen, 85% with the every-three-week regimen, and 69% with the every-four-week regimen. Median overall survival had not yet been reached or estimated after approximately nine months of median follow-up across the three regimens, leaving the most consequential endpoint of all still open to maturation. The apparent survival advantage in the every-three-week arm, in particular, will require longer observation before any conclusions can be drawn.

Safety findings were broadly reassuring. Treatment-emergent and treatment-related adverse event rates were similar across the three dosing regimens, and investigators identified no new or unexpected safety signals. Cytokine release syndrome, the flu-like immune activation event characteristic of T-cell engagers, occurred in 60% to 70% of patients across arms but was predominantly grade 1 or 2 in severity. Immune effector cell-associated neurotoxicity syndrome, a rarer neurological toxicity, was observed in 6% to 12% of patients. Both events were numerically somewhat more frequent in the extended-interval arms, a pattern the researchers noted but did not attribute to a clear mechanism.

Pharmacokinetic analyses offered a mechanistic explanation for why the extended schedules worked as well as they did. Steady-state trough concentrations of tarlatamab were comparable across the three dosing schedules, indicating that increasing the individual dose from 10 mg to 20 mg or 30 mg successfully compensated for the longer gap between administrations. This dose-interval symmetry reflects the drug’s pharmacokinetic behavior, in which total drug exposure over time, rather than the frequency of administration per se, appears to drive both efficacy and tolerability.

Jonathan Goldman, M.D., of the University of California Los Angeles, who presented the findings, emphasized the practical implications. The data suggest that the 20 mg every-three-week and 30 mg every-four-week regimens may offer treatment flexibility for patients with small cell lung cancer, and that alternative dosing schedules for bispecific T-cell engagers generally may achieve outcomes consistent with an established regimen. For patients, fewer clinic visits can translate into less travel, reduced time away from home, and a treatment rhythm that is easier to sustain over months of therapy.

Small cell lung cancer accounts for roughly 10 to 15 percent of lung cancers and is characterized by rapid growth and early dissemination. Although initial platinum-based chemotherapy is often effective, relapse is nearly universal, and options in the second-line setting have historically delivered modest benefit. The arrival of tarlatamab marked the first meaningful expansion of the treatment arsenal in decades, and refining how the drug is delivered could extend its reach to patients for whom biweekly dosing is impractical.

The DeLLphi-309 results arrive amid a broader reassessment of how novel immunotherapies are scheduled. As experience with bispecific antibodies accumulates across hematologic and solid malignancies, investigators are increasingly testing whether dose intensity can be traded for convenience without sacrificing efficacy. For tarlatamab, the descriptive nature of these findings means longer follow-up and additional study will be needed to confirm whether extended-interval dosing can formally match the established every-two-week standard, but for a patient population with few options and significant treatment burdens, the prospect of a three- or four-week schedule represents a meaningful step toward more humane cancer care.

Subject of Research: Extended-interval tarlatamab dosing in previously treated small cell lung cancer evaluated in the Phase 2 DeLLphi-309 trial

Article Title: Extended-interval tarlatamab dosing shows consistent activity and safety in previously treated small cell lung cancer

Article References: Extended-interval tarlatamab dosing shows consistent activity and safety in previously treated small cell lung cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: tarlatamab, small cell lung cancer, DeLLphi-309, bispecific T-cell engager, DLL3, cytokine release syndrome, ICANS, dosing schedule, IASLC, WCLC 2026, immunotherapy, progression-free survival